$KOD

BORGESON JOHN A. sold $142K of KOD

BORGESON JOHN A. (Chief Financial Officer) sold 4,104 shares of Kodiak Sciences Inc. (KOD) at $34.67 ($0.14M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BORGESON JOHN A.
Published Jun 5, 2026, 9:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KOD
Neutral
medium confidence
Mentioned
$KOD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KODNeutralLow
01

Why it matters

The disclosure may slightly influence short-term sentiment, but it does not introduce new information about Kodiak’s pipeline, finances, or regulatory status.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 structure reduces the signal strength versus unscheduled selling.

03

What to watch

Check whether there were multiple insider transactions around the same period or changes in other executives’ holdings; a single Form 4 sale is often noisy.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-05; sale executed 2026-06-04

Background

SEC Form 4 reports an officer’s/direct holdings transaction; this one is an open-market sale by Kodiak Sciences CFO under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$KODNeutralMedium confidence
Context

Kodiak Sciences CFO John A. Borgeson sold 4,104 shares in an open-market transaction under a 10b5-1 plan, disclosed via SEC Form 4.

Expected impact

Low likelihood of a sustained price move; any impact is likely brief unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is an ownership-change disclosure with a pre-arranged 10b5-1 plan; the article provides no new operational/clinical/financial catalyst beyond the sale details.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • Kodiak Sciences Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • John A. Borgeson

    CFO who executed the open-market sale under a 10b5-1 plan.

Related articles